Psilocybin Alcohol Use Disorder: What Hopkins and NYU Research Found

Why Alcohol Use Disorder Is So Hard to Treat

Alcohol use disorder affects tens of millions of people worldwide, and the existing treatment options, while genuinely helpful for some, leave a large gap. Medications like naltrexone and acamprosate reduce cravings in a portion of patients. Behavioral therapies, including cognitive behavioral therapy and motivational enhancement therapy, produce real results but require sustained engagement. Relapse rates remain high across the board.

Part of the difficulty is neurological. Chronic alcohol use reshapes the brain’s reward circuitry, alters how the prefrontal cortex regulates impulse control, and creates deeply entrenched behavioral patterns that are resistant to change even when someone strongly wants to stop. Standard treatments address symptoms and triggers, but they do not necessarily interrupt the underlying neural rigidity that keeps those patterns locked in.

This is part of why researchers began looking seriously at psilocybin, the active compound in certain species of mushrooms, as a potential adjunct treatment for alcohol use disorder. Psilocybin appears to work in ways that differ substantially from conventional pharmacological approaches, and early clinical data suggests it may be capable of producing changes that outlast the experience itself.

The NYU Trial: The First Randomized Controlled Study

The most rigorous published evidence on psilocybin alcohol use disorder treatment comes from a randomized, double-blind, placebo-controlled trial led by Dr. Michael Bogenschutz at the NYU Langone Center for Psychedelic Medicine, published in JAMA Psychiatry in August 2022.

The trial enrolled 93 adults between the ages of 25 and 65, all meeting diagnostic criteria for alcohol dependence and reporting at least four heavy drinking days in the 30 days before screening. Participants received 12 weeks of structured psychotherapy alongside two day-long medicine sessions. Half received psilocybin; the other half received diphenhydramine (an antihistamine) as an active placebo. The blinding was designed to make it difficult for participants to know which group they were in, though the perceptual effects of psilocybin made complete blinding challenging, as the researchers acknowledged.

Outcomes were tracked over 32 weeks following the first dose. The primary measure was percentage of heavy drinking days during the follow-up period. The psilocybin group showed a significantly lower percentage of heavy drinking days compared to the placebo group. Secondary outcomes, including total drinks per day and rates of abstinence, also favored the psilocybin condition. The research team described the reductions as robust, with the effects appearing to consolidate after the second dosing session rather than fading over time.

Importantly, the study also found the treatment was well-tolerated. There were no serious adverse events attributed to psilocybin. Transient increases in blood pressure and heart rate were noted during sessions, consistent with the known pharmacology, and managed in the clinical setting.

What Johns Hopkins Has Contributed

Johns Hopkins has been a central institution in the broader science of psilocybin-assisted treatment for addiction, even as its primary AUD-specific work remains ongoing.

The Hopkins team’s most influential addiction research to date involved tobacco rather than alcohol, but the findings are directly relevant because they involve the same compound and a similar treatment model. A 2014 open-label pilot study led by Dr. Matthew Johnson found that psilocybin, administered in the context of structured cognitive behavioral therapy for smoking cessation, produced 6-month abstinence rates of 80% in a small sample of 15 participants. A follow-up paper found 67% of participants still abstinent at 12 months. These numbers substantially exceed typical outcomes for nicotine replacement or behavioral therapy alone, and they helped establish psilocybin’s credibility as an addiction intervention worth pursuing rigorously.

Johnson, who is also a professor of psychiatry and behavioral sciences at Hopkins, has commented on the broader addiction research landscape, noting that the emerging evidence for psilocybin across different substance use disorders suggests a common mechanism at work, one that may not be limited to any single substance of dependence.

The Hopkins Center for Psychedelic and Consciousness Research has separately documented reductions in alcohol misuse as a secondary finding in its naturalistic use surveys, and has ongoing work examining psilocybin for alcohol use disorder as a distinct research priority.

How Psilocybin May Work on Addiction

Understanding the mechanism behind these outcomes requires a brief look at what psilocybin actually does in the brain, which is more specific than the vague notion of “tripping” often attached to it in public conversation.

Psilocybin is converted in the body to psilocin, which binds primarily to serotonin 5-HT2A receptors, especially in the prefrontal cortex and other areas associated with cognition, self-referential thinking, and emotional regulation. This binding produces a temporary but significant disruption of ordinary brain network activity, particularly in the default mode network (DMN), a set of interconnected regions active during self-focused mental activity, rumination, and habitual thinking.

In addiction, the DMN is thought to play a role in the kind of automatic, self-reinforcing thought patterns that sustain compulsive behavior. Craving, avoidance of discomfort, and the narratives people tell themselves about their drinking are all tied to activity in these networks. Psilocybin appears to temporarily quiet or reorganize this activity, creating a window in which the brain is more plastic, more open to new patterns of association and behavior.

There is also evidence that psilocybin promotes neuroplasticity at the cellular level, potentially allowing new neural connections to form more readily in the short period following a session. This may help explain why the therapeutic gains seen in trials tend to be durable rather than wearing off quickly, and why the quality and depth of the therapeutic preparation and integration work seems to matter significantly for outcomes.

Researchers have also noted that participants in psilocybin trials often describe something they call a shift in perspective: a sense that their relationship to alcohol changed qualitatively, not just behaviorally. Some report that the substance lost its psychological hold, or that they saw their drinking patterns from a distance for the first time. These subjective reports are difficult to quantify, but they are consistent across multiple trials and may point to the experiential component of the treatment as a meaningful variable in its own right, separate from pharmacology alone.

What the Research Does Not Yet Tell Us

It would be a mistake to read the existing findings as proof that psilocybin is a reliable solution for alcohol use disorder. The honest picture is more complicated, and the researchers themselves are careful about this.

Sample sizes are still relatively small. The NYU trial’s 93 participants is the largest controlled study to date, and while that represents meaningful progress, it is well below what would be needed for regulatory approval or broad clinical implementation. The demographic composition of trial participants has also skewed heavily toward educated, white adults, which limits how broadly the findings can be generalized.

Blinding in psychedelic trials presents a persistent methodological challenge. Participants who receive an active psychedelic will almost certainly know it, which introduces expectation effects that are difficult to separate from pharmacological ones. The NYU team used an active placebo to mitigate this, but the problem cannot be fully eliminated with current trial designs.

The role of psychotherapy in producing the outcomes is also not fully resolved. All participants in the NYU trial received structured therapy regardless of their medication assignment. Whether psilocybin alone, therapy alone, or the combination is doing the most work remains an open question. Current protocols treat them as a package, which makes clinical sense given safety considerations, but it complicates interpretation of mechanism.

Phase III trials, which would be large-scale, multi-site, and required for regulatory approval, have not yet been completed for this indication. The field is moving in that direction, but psilocybin-assisted treatment for alcohol use disorder is not yet an approved therapy anywhere.

What This Means for People Considering Their Options

If you are exploring treatment options for alcohol use disorder, the research on psilocybin is worth understanding, though it is not yet something most people can access through established clinical pathways. Psilocybin remains a Schedule I substance in the United States at the federal level, meaning legal therapeutic access is limited to clinical trials and a small number of state-level frameworks.

What the research does suggest is that the conversation about psychedelics addiction treatment has moved well beyond speculation. The NYU trial in particular represents rigorous clinical science published in a leading peer-reviewed journal, and the results warrant serious attention from both researchers and people personally affected by alcohol use disorder.

For anyone considering psychedelic-assisted approaches, whether now or as the regulatory landscape continues to shift, the quality of preparation and integration support is as important as anything that happens during an experience itself. That is not a minor logistical point. It is central to how these treatments have been designed to work in every serious clinical study conducted so far.